Download the webinar slides. The specialty pharmacy industry has dramatically changed over the past few years and is now one of the fastest growing sources of revenue in the prescription drug marketplace. As a result, payers and PBMs... Read More
The impact of Direct and Indirect Remuneration ("DIR") fees on the specialty pharmacy industry cannot be overstated and has been widely reported in White Papers and industry news reports. However, the impact of DIR fees on the 340B sector is only... Read More
In this White Paper, the National Association of Specialty Pharmacy (NASP) and Frier Levitt explore the disparate impact that certain Pharmacy Benefit Managers (PBMs) "Direct and Indirect Remuneration" fees (commonly known as "DIR Fees") have on... Read More
A White Paper by Frier Levitt examines the ongoing practice by Pharmacy Benefit Managers (PBMs) to increase corporate profits through murky "Direct and Indirect Remuneration" fees—commonly known as "DIR Fees"—charged to community oncology... Read More
Plan sponsors and their administrators, such as Pharmacy Benefit Managers (PBMs), are increasingly imposing Direct and Indirect Remuneration ("DIR") fees on independent pharmacies nationwide, with a focus on pharmacies in a... Read More
Pharmacy Benefit Managers (PBMs) own their own Specialty Pharmacies (SPs) and convince Plan Sponsors to allow the PBMs to become the exclusive provider of expensive specialty drugs. PBMs have recently enjoyed significant revenue expansion and... Read More
Frier Levitt marks another successful PBM audit appeal by helping a pharmacy to reduce the initial recoupment amount requested by a PBM by almost $170,000. Frier Levitt is well acquainted with the terms of the various PBM Manuals and understands... Read More
Over the past several months, a new brand of marketing has emerged in the compound pharmacy space, shifting from marketing aimed at prescribing physicians, to direct-to-consumer marketing of compounded pain creams. Using telemarketing techniques or... Read More
